Targeting the B-cell receptor (BCR) signaling pathway in Burkitt lymphoma (BL)

被引：0
|
作者：
Cairo, Mitchell S. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA
[2] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[3] New York Med Coll, Dept Pathol, Microbiol, Valhalla, NY 10595 USA
[4] New York Med Coll, Dept Immunol, Valhalla, NY 10595 USA
[5] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 171卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
43
引用
收藏
页码：27 / 27
页数：1
相关论文
共 50 条
  • [31] Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
    Wilson, Wyndham H.
    Young, Ryan M.
    Schmitz, Roland
    Yang, Yandan
    Pittaluga, Stefania
    Wright, George
    Lih, Chih-Jian
    Williams, P. Mickey
    Shaffer, Arthur L.
    Gerecitano, John
    de Vos, Sven
    Goy, Andre
    Kenkre, Vaishalee P.
    Barr, Paul M.
    Blum, Kristie A.
    Shustov, Andrei
    Advani, Ranjana
    Fowler, Nathan H.
    Vose, Julie M.
    Elstrom, Rebecca L.
    Habermann, Thomas M.
    Barrientos, Jacqueline C.
    McGreivy, Jesse
    Fardis, Maria
    Chang, Betty Y.
    Clow, Fong
    Munneke, Brian
    Moussa, Davina
    Beaupre, Darrin M.
    Staudt, Louis M.
    NATURE MEDICINE, 2015, 21 (08) : 922 - 926
  • [32] Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
    Wyndham H Wilson
    Ryan M Young
    Roland Schmitz
    Yandan Yang
    Stefania Pittaluga
    George Wright
    Chih-Jian Lih
    P Mickey Williams
    Arthur L Shaffer
    John Gerecitano
    Sven de Vos
    Andre Goy
    Vaishalee P Kenkre
    Paul M Barr
    Kristie A Blum
    Andrei Shustov
    Ranjana Advani
    Nathan H Fowler
    Julie M Vose
    Rebecca L Elstrom
    Thomas M Habermann
    Jacqueline C Barrientos
    Jesse McGreivy
    Maria Fardis
    Betty Y Chang
    Fong Clow
    Brian Munneke
    Davina Moussa
    Darrin M Beaupre
    Louis M Staudt
    Nature Medicine, 2015, 21 : 922 - 926
  • [33] Distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma
    Jack, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 61 - 63
  • [34] The B-cell receptor signaling pathway as a therapeutic target in CLL
    Woyach, Jennifer A.
    Johnson, Amy J.
    Byrd, John C.
    BLOOD, 2012, 120 (06) : 1175 - 1184
  • [35] Comparison of Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma (BCL-U) Patient Outcomes: Intensive Therapy May Not Benefit BCL-U
    Bumma, Naresh
    Rybicki, Lisa
    Caimi, Paolo
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad
    Smith, Mitchell R.
    Hill, Brian T.
    BLOOD, 2014, 124 (21)
  • [36] Successful targeting of GnRH receptor in Burkitt lymphoma cell lines
    Rast, S.
    Hauschild, J.
    Dierlamm, J.
    Bokemeyer, C.
    von Amsberg, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 70 - 70
  • [37] B-cell antigen receptor signaling requirements for targeting antigen to the MHC class II presentation pathway
    Clark, MR
    Massenburg, D
    Siemasko, K
    Hou, P
    Zhang, M
    CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (03) : 382 - 387
  • [38] Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma
    Eken, Janneke A.
    Koning, Marvyn T.
    Yanez, Julieta H. Sepulveda
    van Bergen, Cornelis A. M.
    Quinten, Edwin
    Kupcova, Kristyna
    Havranek, Ondrej
    De Groen, Ruben A. L.
    Vermaat, Joost S. P.
    de Jong, Daphne
    Kluin, Philip
    Cleven, Arjen
    Jumaa, Hassan
    Veelken, Hendrik
    BLOOD, 2022, 140 : 6444 - 6445
  • [39] Dysregulation of MYC Driven By BCR-PI3K-AKT Signaling Pathway in Diffuse Large B-Cell Lymphoma
    Wang, Wei-Ge
    Jiang, Xiang-Nan
    Liu, Ze-Bing
    Zhou, Xiao-Yan
    Li, Xiao-Qiu
    LABORATORY INVESTIGATION, 2015, 95 : 385A - 385A
  • [40] Targeting the B cell receptor pathway in non-Hodgkin lymphoma
    Valla, Kelly
    Flowers, Christopher R.
    Koff, Jean L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (06) : 513 - 522
12345